StockNews.com Initiates Coverage on vTv Therapeutics (NASDAQ:VTVT)

StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note released on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, HC Wainwright initiated coverage on shares of vTv Therapeutics in a report on Wednesday, April 9th. They set a “buy” rating and a $36.00 price target for the company.

vTv Therapeutics Trading Up 4.7 %

Shares of VTVT opened at $19.70 on Wednesday. The stock has a market cap of $62.84 million, a PE ratio of -4.35 and a beta of 0.81. vTv Therapeutics has a 1 year low of $12.12 and a 1 year high of $29.19. The stock has a 50 day simple moving average of $18.08 and a 200-day simple moving average of $15.94.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.32. The company had revenue of $0.02 million for the quarter.

Institutional Trading of vTv Therapeutics

An institutional investor recently raised its position in vTv Therapeutics stock. Geode Capital Management LLC increased its stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,634 shares of the biotechnology company’s stock after buying an additional 1,327 shares during the period. Geode Capital Management LLC owned 0.36% of vTv Therapeutics worth $158,000 at the end of the most recent quarter. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.